For research use only. Not for therapeutic Use.
Trifenagrel is a platelet aggregation inhibitor that inhibits the inducing effects of arachidonic acid (AA) and collagen. The ED50s of trifenagrel for inhibiting AA- and collagen-induced platelet aggregation in guinea pigs were 1.4 mg/kg and 9.4 mg/kg, respectively[1].
| Catalog Number | I037498 |
| CAS Number | 84203-09-8 |
| Synonyms | 2-[2-(4,5-diphenyl-1H-imidazol-2-yl)phenoxy]-N,N-dimethylethanamine |
| Molecular Formula | C25H25N3O |
| Purity | ≥95% |
| InChI | InChI=1S/C25H25N3O/c1-28(2)17-18-29-22-16-10-9-15-21(22)25-26-23(19-11-5-3-6-12-19)24(27-25)20-13-7-4-8-14-20/h3-16H,17-18H2,1-2H3,(H,26,27) |
| InChIKey | KGVYOGLFOPNPDJ-UHFFFAOYSA-N |
| SMILES | CN(C)CCOC1=CC=CC=C1C2=NC(=C(N2)C3=CC=CC=C3)C4=CC=CC=C4 |
| Reference | [1]. Abrahams SL, et al. Trifenagrel: a chemically novel platelet aggregation inhibitor. J Pharmacol Exp Ther. 1989 May;249(2):359-65. |
